Nirsevimab Effectiveness Against Severe RSV Infection in the Primary Care Setting.

IF 6.2 2区医学 Q1 PEDIATRICS

Pediatrics Pub Date : 2024-10-04 DOI:10.1542/peds.2024-066393

Mónica López-Lacort, Cintia Muñoz-Quiles, Ainara Mira-Iglesias, F Xavier López-Labrador, María Garcés-Sánchez, Begoña Escribano-López, Matilde Zornoza-Moreno, Jaime Jesús Pérez-Martín, Santiago Alfayate-Miguelez, Antonio Iofrío-De Arce, Eliseo Pastor-Villalba, José Antonio Lluch-Rodrigo, Javier Díez-Domingo, Alejandro Orrico-Sánchez

{"title":"Nirsevimab Effectiveness Against Severe RSV Infection in the Primary Care Setting.","authors":"Mónica López-Lacort, Cintia Muñoz-Quiles, Ainara Mira-Iglesias, F Xavier López-Labrador, María Garcés-Sánchez, Begoña Escribano-López, Matilde Zornoza-Moreno, Jaime Jesús Pérez-Martín, Santiago Alfayate-Miguelez, Antonio Iofrío-De Arce, Eliseo Pastor-Villalba, José Antonio Lluch-Rodrigo, Javier Díez-Domingo, Alejandro Orrico-Sánchez","doi":"10.1542/peds.2024-066393","DOIUrl":null,"url":null,"abstract":"Objectives: This study assesses the effectiveness of nirsevimab, a monoclonal antibody, in preventing medically attended respiratory syncytial virus-lower respiratory tract infections (RSV-LRTI) in a large primary care network in Spain, in both overall and catch-up infants under ten months of age.Methods: The 2023-24 immunization campaign with nirsevimab in Spain targeted all infants born after April 1st, 2023. Those born after October 1st received it at birth in hospitals, while others received it through a catch-up program. The MEDIPRIM network of primary care centers recruited all infants with LRTI for RSV PCR testing and employed a test-negative design (TND) approach to estimate the effectiveness of nirsevimab.Results: The study included 160 infants, 141 (88%) of them received nirsevimab and 128 belonged to the catch-up group (88% received nirsevimab). Overall, RSV was detected in 44 infants (27.5%). Within the catch-up group, 37 (28.9%) were positive for RSV. The overall effectiveness was 75.8% (95% CI: 40.4-92.7), and 80.2% (95% CI: 44.3-95.4) in infants belonging to the catch-up group.Conclusions: This study underscores the effectiveness of nirsevimab in preventing medically attended LRTI in infants in outpatient settings and emphasizes the importance of a catch-up immunization program to reduce the disease burden in primary care.","PeriodicalId":20028,"journal":{"name":"Pediatrics","volume":null,"pages":null},"PeriodicalIF":6.2000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1542/peds.2024-066393","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study assesses the effectiveness of nirsevimab, a monoclonal antibody, in preventing medically attended respiratory syncytial virus-lower respiratory tract infections (RSV-LRTI) in a large primary care network in Spain, in both overall and catch-up infants under ten months of age.

Methods: The 2023-24 immunization campaign with nirsevimab in Spain targeted all infants born after April 1st, 2023. Those born after October 1st received it at birth in hospitals, while others received it through a catch-up program. The MEDIPRIM network of primary care centers recruited all infants with LRTI for RSV PCR testing and employed a test-negative design (TND) approach to estimate the effectiveness of nirsevimab.

Results: The study included 160 infants, 141 (88%) of them received nirsevimab and 128 belonged to the catch-up group (88% received nirsevimab). Overall, RSV was detected in 44 infants (27.5%). Within the catch-up group, 37 (28.9%) were positive for RSV. The overall effectiveness was 75.8% (95% CI: 40.4-92.7), and 80.2% (95% CI: 44.3-95.4) in infants belonging to the catch-up group.

Conclusions: This study underscores the effectiveness of nirsevimab in preventing medically attended LRTI in infants in outpatient settings and emphasizes the importance of a catch-up immunization program to reduce the disease burden in primary care.

查看原文本刊更多论文

尼舍单抗在基层医疗机构预防严重 RSV 感染的有效性

研究目的本研究评估了单克隆抗体 nirsevimab 在西班牙一个大型初级保健网络中预防医疗护理的呼吸道合胞病毒-下呼吸道感染（RSV-LRTI）的有效性，研究对象为 10 个月以下的全部婴儿和补种婴儿：西班牙 2023-24 年的尼舍单抗免疫接种活动针对的是 2023 年 4 月 1 日之后出生的所有婴儿。10月1日后出生的婴儿在出生时在医院接种，其他婴儿则通过补种计划接种。MEDIPRIM 初级保健中心网络招募所有患有 LRTI 的婴儿进行 RSV PCR 检测，并采用检测阴性设计 (TND) 方法来估算 nirsevimab 的有效性：研究共纳入 160 名婴儿，其中 141 人（88%）接受了尼舍单抗治疗，128 人属于补足组（88% 接受了尼舍单抗治疗）。共有 44 名婴儿（27.5%）检测到 RSV。在补足组中，37 名婴儿（28.9%）的 RSV 检测呈阳性。总体有效率为 75.8%（95% CI：40.4-92.7），补足组婴儿的有效率为 80.2%（95% CI：44.3-95.4）：这项研究强调了尼舍单抗在预防门诊婴儿LRTI方面的有效性，并强调了补种免疫计划对减少初级保健中疾病负担的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatrics 医学-小儿科

CiteScore

12.80

自引率

5.00%

发文量

791

审稿时长

2-3 weeks

期刊介绍： The Pediatrics® journal is the official flagship journal of the American Academy of Pediatrics (AAP). It is widely cited in the field of pediatric medicine and is recognized as the leading journal in the field. The journal publishes original research and evidence-based articles, which provide authoritative information to help readers stay up-to-date with the latest developments in pediatric medicine. The content is peer-reviewed and undergoes rigorous evaluation to ensure its quality and reliability. Pediatrics also serves as a valuable resource for conducting new research studies and supporting education and training activities in the field of pediatrics. It aims to enhance the quality of pediatric outpatient and inpatient care by disseminating valuable knowledge and insights. As of 2023, Pediatrics has an impressive Journal Impact Factor (IF) Score of 8.0. The IF is a measure of a journal's influence and importance in the scientific community, with higher scores indicating a greater impact. This score reflects the significance and reach of the research published in Pediatrics, further establishing its prominence in the field of pediatric medicine.